To determine safety profile of azithromycin in Covid-19 patients

Khadija ASİF; Farhat ABBAS; Umar JAVAİD SANDHU

Makale detayları

To determine safety profile of azithromycin in Covid-19 patients

Yazarlar:

Khadija ASİF | Farhat ABBAS | Umar JAVAİD SANDHU

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Journal of Experimental and Clinical Medicine 2022 Vol.39 Issue 1, pp.32-35

Belge Tipi:

Makale

Yayın Tarihi:

12/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000507011

Sıklık:

Üç Aylık

eISSN:

1309-5129

pISSN:

1309-4483

Özet:

 

At the end of the year 2019, a novel virus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV or COVID-19) first appeared in the Chinese city of Wuhan and the WHO declared the novel coronavirus disease as a global pandemic on March, 11th 2020. Corona Virus is RNA virus, major virus that affects respiratory system and can result in acute respiratory distress syndrome, so there emerged several management strategies to combat the challenge of the disease. Azithromycin is one of those treatment options. Azithromycin have been used widely and generally considered as safe medication. The design of this study is Cross-Sectional Study. The 80 Covid-19 positive in ICU were given Azithromycin along with other standard treatment, Side effects were divided into mild serious and allergic reactions. These were noted down in pre designed proforma. Data analysis was done in SPSS version 25. 80 patients were studied 38 (46.2%) patients experienced side effects, majority of which were mild in nature, Out of 80 patients Abdominal Pain was 37.5%, diarrhea 22.7% nausea 25%, transaminitis 2.5%, anorexia 26.3%, taste perversion 36.3%, dyspepsia 15%, vomiting 17.5%, headache 6.3% and somnolence 1.3%. Only 1 (1.25%) patients had arrhythmia and 1 (1.25%) had urticaria that was successfully treated. After this study this can be concluded that Azithromycin is safe drug as majority of side effects experienced were mild in nature and it can be safely used to treat Covid-19 positive patients.

Makale detayları

To determine safety profile of azithromycin in Covid-19 patients

Yazarlar: Khadija ASİF | Farhat ABBAS | Umar JAVAİD SANDHU

Yayıncı: Ondokuz Mayıs University

Ana Başlıklar: Sağlık teşvikleri

Dergi: Journal of Experimental and Clinical Medicine 2022 Vol.39 Issue 1, pp.32-35

Belge Tipi: Makale

Yayın Tarihi: 12/2021

Belge Dili: İngilizce

Document ID (Org No.): 2000507011

Sıklık: Üç Aylık

eISSN: 1309-5129

pISSN: 1309-4483

Sayı

Yazarlar:

Khadija ASİF | Farhat ABBAS | Umar JAVAİD SANDHU

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Journal of Experimental and Clinical Medicine 2022 Vol.39 Issue 1, pp.32-35

Belge Tipi:

Makale

Yayın Tarihi:

12/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000507011

Sıklık:

Üç Aylık

eISSN:

1309-5129

pISSN:

1309-4483